Skip to main content
. 2017 Nov 6;8(62):105472–105478. doi: 10.18632/oncotarget.22295

Figure 1. Effects of rs699947 and rs833061 polymorphisms on PFS among CRC patients receiving BEV treatments.

Figure 1

There was no significant association between rs699947 polymorphism with PFC (log rank test, P=0.392). While rs833061 polymorphism showed obvious correlation with PFS among the study population (log rank test, P=0.002). TT carriers had a significantly better PFS than CC carriers (log rank test, P=0.001), while patients carrying TC genotype had obviously better PFS than those carrying CC genotype (log rank test, P=0.013). There was no remarkable difference between TT carriers and TC carriers (log rank test, P=0.126). The significant level was adjusted by Bonferroni method, α=0.017.